Why foreign firms are betting big on China's biopharma future

China's biopharma boom is on, and foreign investors are flooding in. As we dive into the billion-dollar wave of foreign investment reshaping China's biotech landscape, check out Why pharma giants like Roche and AstraZeneca are expanding their footprint here. What strategic edge does China offer in global drug development? And can the country become a global biopharma innovation powerhouse by 2030? Host Tu Yun joins Dr. Zhou Mi, the Deputy Director of the Institute of American and Oceania Study, Chinese Academy of International Trade and Economic Cooperation, Warwick Powell, an Adjunct Professor at Queensland University of Technology in Australia, and Chen Jiahe, the Chief Investment Officer of Beijing-based Novem Arcae Technologies for a close look.